生殖支原体的表型抗生素耐药性及其在不同大环内酯类耐药相关突变间的差异
研究生殖支原体尿液标本与Vero细胞共培养后对8种抗生素行表型药敏试验,40份阳性尿标本中20份(50.0%)培养成功。不同大环内酯类耐药相关突变(MRAM)间阿奇霉素生长抑制存在差异,A2058T在阿奇霉素4、8、16、32 mg/L时生长抑制分别较A2058G高24、7、15、12倍(P < 0.01)。
要点
- 40份核酸阳性的尿液标本中20份(50.0%)经与Vero细胞共培养成功分离出生殖支原体。
- 阿奇霉素MIC范围0.008->32 mg/L,左氧氟沙星1-4 mg/L,莫西沙星<0.25-1 mg/L。
- A2058T在阿奇霉素4、8、16、32 mg/L时生长抑制分别较A2058G高24、7、15、12倍(P < 0.01)。
核心结论
- 生殖支原体分离株在不同MRAM间对阿奇霉素诱导的生长抑制存在差异,可能解释临床疗效差异。
- 其他抗生素的表型药敏试验显示MIC相对较低。
- 未来研究应结合临床疗效与症状严重程度以优化生殖支原体治疗。
研究设计与样本
- 研究将核酸扩增检测阳性的尿液标本与Vero细胞共培养,对8种抗生素进行表型药敏试验。
- 40份阳性尿标本中20份(50.0%)培养成功,表型药敏在部分亚组中检测。
- 比较不同MRAM间阿奇霉素对生殖支原体的生长抑制与MIC。
主要发现
- MIC范围:阿奇霉素0.008->32 mg/L,左氧氟沙星1-4 mg/L,莫西沙星<0.25-1 mg/L,西他沙星<0.032-0.25 mg/L。
- MIC范围:米诺环素<0.25-1 mg/L,多西环素<0.125-2 mg/L,大观霉素<2.5->25 mg/L,来法莫林<0.004-0.063 mg/L。
- A2058T在阿奇霉素4、8、16、32 mg/L时生长抑制分别较A2058G高24、7、15、12倍(P < 0.01)。
- 对MIC范围影响由低到高依次为:野生型(0.008-0.016)、A2058T(8-32)、A2059G(≥32)、A2058G(>32)。
局限性
- 未来研究应结合临床治疗疗效与症状严重程度以优化生殖支原体治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Mycoplasma genitalium, a sexually transmitted bacterium, faces increasing antibiotic resistance, particularly to azithromycin. However, presence of macrolide resistance-associated mutations (MRAMs) does not evidently implicate azithromycin treatment failure. This study aimed to establish an in vitro co-culture system of M. genitalium isolates and perform phenotypic susceptibility testing for different antibiotics, focusing on azithromycin to evaluate genotypic and phenotypic resistance across MRAMs. METHODS: Urine specimens testing positive for M. genitalium via nucleic acid amplification were co-cultured with Vero cells. Phenotypic susceptibility testing was performed for eight antibiotics. Growth inhibition and MIC of M. genitalium by azithromycin were compared across different MRAMs. RESULTS: M. genitalium was cultured from 20/40 (50.0%) positive urine samples, with phenotypic susceptibility tested in a subset. MICs ranged as follows: azithromycin (0.008->32 mg/L), levofloxacin (1-4 mg/L), moxifloxacin (<0.25-1 mg/L), sitafloxacin (<0.032-0.25 mg/L), minocycline (<0.25-1 mg/L), doxycycline (<0.125-2 mg/L), spectinomycin (<2.5->25 mg/L) and lefamulin (<0.004-0.063 mg/L). Isolates with A2058T demonstrated 24-, 7-, 15- and 12-fold increases in growth inhibition compared with A2058G at azithromycin concentrations of 4, 8, 16 and 32 mg/L, respectively (P < 0.01). MRAMs ranked from low to high impact on MIC range were as follows: wildtype (0.008-0.016), A2058T (8-32), A2059G (≥32) and A2058G (>32). CONCLUSIONS: This study revealed that M. genitalium isolates vary in azithromycin-induced growth inhibition across MRAMs, potentially explaining differences in clinical treatment efficacy. Phenotypic susceptibility testing for other antibiotics demonstrated relatively low MICs. Future studies should incorporate clinical treatment efficacy and symptom severity to optimize treatment for M. genitalium.
引用
- Doelman TA, Adriaens N, Westerhuis BM, et al. Phenotypic antibiotic resistance of Mycoplasma genitalium and its variation between different macrolide resistance-associated mutations. J Antimicrob Chemother. 2025. PMID: 39656801. doi:10.1093/jac/dkae430
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。